The first Dutch SDHB founder deletion in paraganglioma-pheochromocytoma patients. by Bayley, J.P.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81280
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BioMed Central
Page 1 of 10
(page number not for citation purposes)
BMC Medical Genetics
Open AccessResearch article
The first Dutch SDHB founder deletion in paraganglioma – 
pheochromocytoma patients
Jean-Pierre Bayley*1, Anneliese EM Grimbergen2, Patrick A van Bunderen2, 
Michiel van der Wielen2, Henricus P Kunst3, Jacques W Lenders5, 
Jeroen C Jansen3, Robin PF Dullaart6, Peter Devilee1, Eleonora P Corssmit4, 
Annette H Vriends2, Monique Losekoot2 and Marjan M Weiss2
Address: 1Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands, 2Department of Clinical Genetics, Leiden 
University Medical Center, Leiden, The Netherlands, 3Department of Otorhinolaryngology, Leiden University Medical Center, Leiden, The 
Netherlands, 4Department of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands, 5Department of Internal Medicine, 
Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands and 6Department of Endocrinology, University of Groningen and 
University Medical Center Groningen, Groningen, The Netherlands
Email: Jean-Pierre Bayley* - j.p.l.bayley@lumc.nl; Anneliese EM Grimbergen - J.E.M.A.Grimbergen@lumc.nl; Patrick A van 
Bunderen - P.A.van_Bunderen@lumc.nl; Michiel van der Wielen - M.J.R.van_der_Wielen@lumc.nl; Henricus P Kunst - H.Kunst@kno.umcn.nl; 
Jacques W Lenders - j.lenders@aig.umcn.nl; Jeroen C Jansen - J.C.Jansen@lumc.nl; Robin PF Dullaart - r.p.f.dullaart@int.umcg.nl; 
Peter Devilee - P.Devilee@lumc.nl; Eleonora P Corssmit - E.P.M.van_der_Kleij@lumc.nl; Annette H Vriends - A.H.J.T.Vriends@lumc.nl; 
Monique Losekoot - M.Losekoot@lumc.nl; Marjan M Weiss - j.weiss@vumc.nl
* Corresponding author    
Abstract
Background: Germline mutations of the tumor suppressor genes SDHB, SDHC and SDHD play a major
role in hereditary paraganglioma and pheochromocytoma. These three genes encode subunits of succinate
dehydrogenase (SDH), the mitochondrial tricarboxylic acid cycle enzyme and complex II component of
the electron transport chain. The majority of variants of the SDH genes are missense and nonsense
mutations. To date few large deletions of the SDH genes have been described.
Methods: We carried out gene deletion scanning using MLPA in 126 patients negative for point mutations
in the SDH genes. We then proceeded to the molecular characterization of deletions, mapping
breakpoints in each patient and used haplotype analysis to determine whether the deletions are due to a
mutation hotspot or if a common haplotype indicated a single founder mutation.
Results: A novel deletion of exon 3 of the SDHB gene was identified in nine apparently unrelated Dutch
patients. An identical 7905 bp deletion, c.201-4429_287-933del, was found in all patients, resulting in a
frameshift and a predicted truncated protein, p.Cys68HisfsX21. Haplotype analysis demonstrated a
common haplotype at the SDHB locus. Index patients presented with pheochromocytoma, extra-adrenal
PGL and HN-PGL. A lack of family history was seen in seven of the nine cases.
Conclusion: The identical exon 3 deletions and common haplotype in nine patients indicates that this
mutation is the first Dutch SDHB founder mutation. The predominantly non-familial presentation of these
patients strongly suggests reduced penetrance. In this small series HN-PGL occurs as frequently as
pheochromocytoma and extra-adrenal PGL.
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Background
Paragangliomas occur as tumors of parasympathetically
innervated head and neck paraganglia (HN-PGL), as intra-
abdominal and thoracic extra-adrenal paragangliomas of
the sympathetic paraganglia, and as pheochromocytomas
(PCC) of the adrenal medulla. Sympathetic paraganglio-
mas may present clinically with hypertension, sweating
and palpitations due to catecholamine excess, and espe-
cially in cases with extra-adrenal localization, they may be
metastatic and aggressive. HN-PGL usually follows a mild
course but may lead to significant morbidity due to com-
promised function of cranial nerves.
Although many paragangliomas are apparently sporadic
(i.e. no known family history), many patients will carry a
germline mutation, and worldwide up to 30% of all cases
can be shown to have familial antecedents [1].
The identification in HN-PGL families of germline muta-
tions of SDHD (succinate dehydrogenase, subunit D) [2]
was soon followed by the identification of germline muta-
tions in SDHB [3] and SDHC [4]. These three genes
encode subunits of the mitochondrial tricarboxylic acid
cycle enzyme, succinate dehydrogenase (SDH). SDH also
acts as the complex II component of the electron transport
chain, locating SDH at the center of cellular metabolism.
Despite the fact that SDH is thought to act solely as a uni-
fied protein complex, mutations of subunit genes lead to
striking differences in clinical phenotype. While muta-
tions of SDHD are associated predominantly with HN-
PGL, frequently multifocal and generally non-meta-
static,SDHB mutation carriers frequently present with
PCCs and extra-adrenal paragangliomas, and mutations
of SDHB are more often found in patients with aggressive,
metastatic disease [5]. Until recently mutations of SDHC
were exclusively associated with HN-PGL, but have now
also been identified in patients with PCC [6,7].
The majority of mutations of the SDH genes described in
the SDH mutation database [8]http://chromium.liacs.nl/
lovd_sdh/home.php are missense and nonsense muta-
tions (n = 225). To date only ten distinct large deletions of
the SDH genes have been described.
Although nearly all familial paraganglioma in the Nether-
lands is accounted for by the Dutch SDHD founder muta-
tions p.Asp92Tyr and p.Leu139Pro [9], several Dutch
families carrying an SDHB mutation were recently identi-
fied [10]. Here we describe the results of SDHB gene dele-
tion scanning of 126 paraganglioma-PCC patients. Nine
apparently unrelated Dutch patients all showed deletions
of exon 3 of the SDHB gene. In order to determine if exon
3 is affected by a deletion hotspot, we proceeded to the
molecular characterization of the deletion, mapping the
breakpoint in each patient, and used haplotype analysis to
determine whether the patients share any common haplo-
type, which would suggest a single novel founder muta-
tion. In addition, the clinical phenotype of these patients
is described.
Methods
Patients
Between 2000 and 2008, a total of 251 index patients with
either a paraganglioma or PCC were referred for molecu-
lar testing of the SDHD/B/C genes to the Molecular Genet-
ics Laboratory at the Leiden University Medical Center,
The Netherlands. Informed consent was obtained for
DNA testing according to protocols approved by LUMC
Ethics Review Board. DNA was available from 126 index
patients who tested negative for SDHD point mutations
and in whom point mutations of SDHB and SDHC were,
in most cases, also excluded.
Multiplex ligation dependent probe amplification
MLPA was carried out with the P226 MLPA kit http://
www.mrc-holland.com, containing probes for all exons of
the SDHB, SDHC and SDHD genes, as well as probes
located in the promoter of each gene (27 different
probes). MLPA analysis was performed according to the
MRC Holland protocol [11] except that all reagents in the
kit were used at 1/2 of the recommended volume and
hybridization time was reduced from 16 to 2.5 hours. No
difference in results was seen compared to recommended
conditions.
Haplotype analysis
Analysis of haplotypes by polymorphic di- and tetra
nucleotide markers (microsatellite markers) was per-
formed according to standard procedures (details availa-
ble upon request), using the following markers: D1S436,
D1S2697, D1S170, D1S3669, D1S2826 and D1S2644.
The distance between the last and the first marker is ~3.35
Mb. In addition, intragenic SNPs were sequenced to refine
the haplotype (Table 1). The frequency of marker alleles
in the Dutch population was determined in 24 healthy
controls.
Breakpoint characterization
Long range PCR using the primers F2 (5'-TCT GTT GTG
CCA GCA AAA TG-3') and R4 (5'-CAA ATC CTG CCC TGA
AAA AC-3') was carried out using the Takara LA Taq kit
(Takara Bio Inc., Lucron Bioproducts B.V., Gennep, The
Netherlands) following the manufacturers recommenda-
tions. The resulting PCR fragment of 8.5 kb in the patients
carrying the deletion was subjected to restriction mapping
using the following twelve enzymes: Alw44I, BglI, BglII,
BsaHI, BspEI, EcoRI, Mph1103I, NdeI, SacI, ScaI, SmaI,
XbaI. Analysis of the resulting restriction patterns nar-
rowed the specific region of the deletion, and was fol-
lowed by the design of primers 2162 (5'-CCA GTC CAT
GAA AGG CAA-3') and 2164 (5'-GCT CCA TGT GTC ACG
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Table 1: Name and physical location of chromosome 1 microsatellite markers and intragenic SNPs used for haplotyping
Marker name (in chromosomal order) Chromosomal location (UCSC Genome Browser. Human Mar. 2006 Assembly)
D1S436 15643044
D1S2697 16192037
D1S170 17070023
SDHB gene 17217812
rs12045097 17218463
rs2871775 17218491
rs978528 17222384
rs2235931 17222541
rs2235930 17222729
rs2647162 17222829
rs12142244 17223517
rs2235929 17223682
rs7550829 17230163
rs2746467 17230201
rs11577071 17231760
rs4920390 17231880
rs10887990 17231972
rs11203284 17242538
rs11203285 17242706
rs10887992 17242799
rs10887993 17242827
c.200+987C>T
rs11203287 17244983
rs9435747 17245053
rs11582579 17245097
rs6690934 17245208
rs7536679 17247249
rs7545499 17247274
BMC Medical Genetics 2009, 10:34 http://www.biomedcentral.com/1471-2350/10/34
Page 4 of 10
(page number not for citation purposes)
TGT TT-3'). This allowed the amplification of a 1.6 kb
fragment in patients carrying the deletion but not in
healthy controls. The PCR product was sequenced, and
analyzed using the Multalin program http://bio
info.genopole-toulouse.prd.fr/multalin/multalin.html.
Sequence analysis of the SDHB gene was performed
according standard procedures (details available upon
request), using the NT_004610.18 reference sequence.
Results
MLPA analysis
MLPA allows the detection of large deletions, and is based
on the quantification of multiplexed amplified DNA frag-
ments. It was first described by Schouten et al. in 2002
[11] and due to reliability and ease of use has been widely
adopted in both research and diagnostic settings.
All 251 index patients were screened for germline muta-
tions in SDH genes by sequence analysis. A pathogenic
mutation was identified in 125 patients (50%). MLPA
analysis was performed in 126 mutation negative
patients, and included all exons and the promoter of the
SDHB, SDHC and SDHD genes. Deletions of the SDHB
gene were detected in nine patients, all affecting exon 3
(figure 1). Four deletions were identified in the SDHC and
SDHD genes and will be described elsewhere. In the entire
series 13 of 251 patients (5%) were found to have dele-
tions, representing approximately 10% of all mutations
found. To further characterize the SDHB deletions and
confirm the MLPA results, a long range PCR flanking exon
3 was designed. While the expected normal fragment (~16
kb) could barely be detected, all patients carrying exon 3
deletions showed a shorter fragment of ~9 kb (figure 2).
rs7545518 17247328
SDHB gene 17253252
D1S3669 17556185
D1S2826 18205820
D1S2644 18799054
Table 1: Name and physical location of chromosome 1 microsatellite markers and intragenic SNPs used for haplotyping (Continued)
An example of MLPA analysis of the SDHB, SDHC and SDHD genesFigure 1
An example of MLPA analysis of the SDHB, SDHC and SDHD genes. Only some exons of each gene can be seen in 
this view but all are included in the kit (P226 MLPA kit), plus the promoters of each gene, and several control fragments 
located on various chromosomes. Red peaks show the average of normal control DNA and blue peaks represent the DNA of 
the patient. The deletion of exon 3 of SDHB can clearly be seen (small red diamond).
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Breakpoint characterization
Restriction mapping of the 9 kb SDHB fragment was car-
ried out using twelve enzymes. Analysis of restriction pat-
terns narrowed the breakpoints to small regions of intron
2, approximately 4.5 kb upstream of exon 3 and to a
region 3.5 kb downstream, in intron 3. Primers were
designed around the expected site of the deletion, and a
1.6 kb fragment could be amplified in all patients carrying
the deletion, indicating that all deletions were either iden-
tical or mapped to a small and specific region, which
would suggest a mutation hotspot.
Sequencing of the 1.6 kb PCR product revealed identical
breakpoints in all samples, resulting in a deletion of 7905
bp, including exon 3 (figure 3), suggesting a single
founder mutation, identical by descent. Following HGVS
cDNA nomenclature, the deletion is correctly described as
c.201-4429_287-933del. The deletion of exon 3 is pre-
dicted to result in a frameshift at the DNA level and a trun-
cated protein, p.Cys68HisfsX21.
Although analysis of the surrounding sequence revealed
that the upstream breakpoint is located in an AluSz repeat,
the downstream breakpoint is located in unique
sequence, rather than in an Alu repeat. Thus there are no
repeat sequences or sequence similarity around the break-
point that would suggest a mechanism of deletion or loca-
tion of a mutational hotspot.
Haplotype analysis
Although the patients had no apparent family connection,
all are natives of the Netherlands and share an identical
SDHB deletion.
Therefore we carried out haplotype analysis with six di-
and tetra nucleotide polymorphic markers surrounding
the SDHB gene. Haplotyping was refined by typing addi-
tional intragenic SNPs. A common haplotype could be
deduced in all patients (figure 4), indicating descent from
a common ancestor. The marker haplotype formed by
D1S436, D1S2697, and D1S170 has a frequency of 1% in
the Dutch population, and the likelihood of nine unre-
lated cases carrying this haplotype is ~1.4 × 10-18. Certain
haplotypes have apparently mutated or recombined in
selected patients, an indication that they are only distantly
related.
Clinical data
Patient BD1 presented with a hard mass in the neck at 41
years of age, initially suspected to be an aneurysm, but no
other symptoms. MRI imaging revealed a large and highly
vascular mass, 4 × 2 cm, at the carotid bifurcation, par-
tially displacing the larynx. A second tumor was visible
above the primary mass, apparently a secondary process
of the carotid body tumor. Biopsy and pathological eval-
uation confirmed the diagnosis.
Patient BD2 was diagnosed with both a malignant extra-
adrenal paraganglioma and a parathyroid tumor at the
age of 60. The patient's brother was diagnosed at the age
of 50 with a PCC, and their mother had possibly been
treated for a malignant PCC.
Patient BD3 presented at the age of 35 with a right sided
jugulotympanic paraganglioma, in combination with
raised dopamine levels. MRI of the head and neck
revealed no further tumors. A partial resection was carried
out in 2007, following complaints of reduced hearing and
tinnitus. MRI of the head and neck revealed no further
tumors. Although increased urinary dopamine excretion
indicated a possible occult sympathetic paraganglioma,
MRI of the thorax and abdomen revealed no further
tumors. The patient had a negative family history.
Patient BD4 presented with a retroperitoneal paragangli-
oma directly under the diaphragm and a paraganglioma
of the urinary bladder at the age of 28. No other tumors
were found. A recent MRI scan, nine years after the initial
treatment, revealed no further tumors. The patient had a
clinically negative family history, and although the
patient's mother also has the mutation, she remains unaf-
fected at the age of 66.
A female patient BD5, presented with bilateral carotid
body paraganglioma at 51 yrs, and 15 years later the
patient was found to have raised urine normetanephrine
and dopamine levels. In addition to visualization of the
largest left-sided carotid body paraganglioma by 111In-
octreotide scintigraphy, DOPA-PET and FDG PET-scan-
ning revealed a suspicious lesion in the abdomen, suggest-
Long range PCR of the exon 3 region of SDHBFigure 2
Long range PCR of the exon 3 region of SDHB. Lanes 1 
& 3. Patients carrying deletions showed an anomalous frag-
ment of ~9 kb. Lanes 2 & 4. Two healthy controls lack the 
anomalous ~9 kb fragment. The normal fragment (~16 kb) is 
weakly visible in all lanes. A PCR control fragment of ~4.7 kb 
is also visible in all lanes.
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ing co-existing extra-adrenal paraganglioma. Due to the
risk of co-morbidity, the lesions are being followed con-
servatively.
Patient BD6 presented with a malignant extra-adrenal par-
aganglioma with bone metastases at the age of 12, and a
pituitary tumor. The paternal grandfather is known to
have had a pituitary tumor. The family history is negative
for paraganglioma.
Patient BD7, a 55-year old male, presented with a left
sided carotid body paraganglioma, which was resected at
the age of 50. To date there is no increased excretion of
urinary catecholamine's or their O-methylated metabo-
lites. A recent MRI of the thorax and abdomen revealed no
additional paragangliomas. No family history was availa-
ble.
Patient BD8 presented with a jugulotympanic paragangli-
oma at the age of 18. Recently, at the age of 51 years, MRI
of the head and neck and CT of the thorax revealed that
the patient had developed no further tumors. No clear
family history was available.
Patient BD9 was recently diagnosed, at the age of 28, with
a retroperitoneal presacral paraganglioma without raised
catecholamine levels. MIBG, DOPA-PET and FDG of the
head, neck and thorax revealed no further tumors. The
family history is negative.
Clinical details for all nine patients are shown in overview
(Table 2).
Discussion
While the majority of SDH-related hereditary HN-PGL
and PCC patients carry missense and nonsense mutations,
a significant proportion of patients may carry whole gene
or exon deletions. In the entire current series of patients
13 of 251 (5%) were found to have deletions, represent-
ing 10% of all mutations found. These data have clear
implications for diagnostic DNA screening and indicate
that deletion scanning such as MLPA should be consid-
ered once patients have tested negative by sequencing.
Ten deletions affecting SDH genes have been described to
date. McWhinney et al. first described deletions of SDHB
and SDHD in two families in 2004 [12]. While a large
SDHD deletion was associated with HN-PGL in one family,
a deletion of exon 1 of SDHB in a Brazilian family resulted
in extra-adrenal PGL, together with HN-PGL. Baysel et al.
described a family carrying a deletion affecting exon 6 of
SDHC, and including five affected members, all with HN-
PGL [13]. Cascon et al. subsequently described deletions of
SDHB in families from the Iberian peninsula, [14] identify-
Characterization of the exon 3 SDHB breakpointFigure 3
Characterization of the exon 3 SDHB breakpoint. The lower box shows a patient sequence spanning the deletion. The 
upper figure indicates the approximate location of each portion of the sequence in respective introns in the normal undeleted 
gene sequence.
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ing the first whole gene deletion of SDHB and a deletion of
exon 1. This latter deletion was shown to be a founder on
further characterization and an additional unique exon 1
deletion was identified in a French family [15]. These
patients showed predominantly retroperitoneal PGL, but
two cases from the French family developed adrenal PCC.
Amar et al. have recently described a novel deletion of
SDHB in a patient studied in relation to metastatic para-
ganglioma [16]. This deletion was not further character-
ized. Fish et al. reported a mixed picture of both HN-PGL
and extra-adrenal PGL in a family with a deletion of exon
3 of SDHD [17]. Pasini et al. have described a patient who
presented at 9 years of age with multiple GISTs, and by the
age 16 had developed multiple retroperitoneal paragang-
liomas. This patient showed a large deletion affecting
SDHB, but as no tumor material was available, the rela-
tion of SDHB to the GIST could not be demonstrated [18].
Pigny et al. have reported a deletion of SDHB exons 7 & 8
in a patient with bilateral pheochromocytoma [19].
The clinical features of the SDHB exon 3 deletion patients
described in this report differ from most of the reports
described above in the higher than expected frequency of
HN-PGL. Previous studies have shown that SDHB muta-
tions predominantly predispose to abdominal or thoracic
paragangliomas and adrenal PCC [20], but as Leiden is a
national referral centre for HN-PGL, a referral bias may be
operating.
Although relatively few deletions have thus far been
described, the current picture does not indicate that the
phenotype caused by deletions differs substantially from
that of missense and nonsense mutations. While muta-
tions of SDHB and SDHD show an intriguing divergence
in related phenotypes despite the intimate association of
the protein subunits, gene deletions are unlikely to show
specific genotype-phenotype effects, relative to truncating
or missense mutations, because all mutations are
assumed to result in loss of protein function.
The best current estimates of penetrance for SDHB muta-
tions are 77% at 50 years [20] and approximately 60% at
50 yrs [5]. These figures are based largely on index cases,
as few patients present in the context of extended families.
Such estimates are known to exaggerate penetrance, and
more accurate estimates will require large SDHB-related
families, and the inclusion and detailed clinical screening
Haplotype analysis of patients carrying the SDHB exon 3 deletionFigure 4
Haplotype analysis of patients carrying the SDHB exon 3 deletion. Microsatellites flanking SDHB and intragenic SNPs 
demonstrate a common haplotype. The common haplotype and the region deleted are indicated.
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of apparently unaffected mutation carriers in addition to
patients.
The only large family described to date [21] suggests a
much lower penetrance but there was no detailed clinical
screening of mutation carriers and the authors made no
attempt to estimate penetrance. The fact that SDHB germ-
line mutation carriers often present as apparently non-
familial cases has not escaped various authors [5,22-24]
and even proven founder mutations of SDHB may ini-
tially present as isolated families [15] (and this study).
In contrast, SDHD-related mutations show a very high
penetrance, over 80% at 50 years [5], and also show a
striking and unique imprinted or parent-of-origin inherit-
ance [25], showing almost complete penetrance with
paternal inheritance, while mutation carriers via the
maternal line remain tumor-free throughout life. This is in
sharp contrast with the SDHB and SDHC genes, located
on chromosome 1, which do not show parent-of-origin
inheritance. All evidence indicates that it is not the SDHD
gene itself which is imprinted [2,26] but that some addi-
tional locus on chromosome 11 is involved.
The major imprinted locus of the human genome is on
chromosome 11p15.5, and we have proposed a model in
which an imprinted and maternally expressed gene on
chromosome 11p15.5 must be lost together with the nor-
mal maternal SDHD allele (the paternal allele is inacti-
vated by a germline mutation) prior to initiation of
tumorigenesis [26]. This mechanism, recently referred to
as the 'Hensen model' [27], is supported by additional
data for chromosome 11 [28] and may also play a role in
chromosome 3-linked VHL PCC [29,30].
This model could provide a genetic explanation for the
reduced penetrance of SDHB mutations, in which both
SDHB and the modifier must be lost, requiring loss on
two separate chromosomes; intrinsically less likely than a
single genetic event (whole chromosome loss) which has
been shown to be the mechanism in SDHD tumors
[26,28]. Alternatively or additionally, the difference in
penetrance may have a (partly) biochemical explanation,
related to the difference in function of the SDHD and
SDHB subunits, the former principally structural, the lat-
ter catalytic. A unique biochemical effect of SDHB muta-
tions seems likely in the light of the differing location and
often aggressive behavior of tumors, and the high number
of clinically penetrant mutations identified. No current
model of PGL tumorigenesis can explain these phenom-
ena [31,32].
Conclusion
We describe the first Dutch founder mutation of SDHB, a
novel deletion of exon 3. Index patients presented with
PCC, extra-adrenal PGL as well as HN-PGL. Lack of a clear
Table 2: Clinical summary of patients and family members with the SDHB exon 3 deletion
Patient ID Age at Diagnosis Gender Family Clinical History Clinical Features
BD1 41 Female Negative Carotid body paraganglioma, left
BD2 NA Female Mother & brother with pheochromocytoma Extra adrenal pheochromocytoma
Parathyroid tumor
BD3 35 Male Negative Jugulotympanic paraganglioma with raised 
catecholamine levels. No evidence of 
pheochromocytoma
BD4 28 Male Negative Retroperitoneal paraganglioma and paraganglioma of 
the urinary bladder
BD5 51 Female NA Bilateral carotid body paraganglioma. Raised urine 
normetanephrine and dopamine levels, possible 
extra-adrenal paraganglioma
BD6 12 Female Negative Malignant extra-adrenal paraganglioma with bone 
metastases. Pituitary tumor. Paternal grandfather had 
pituitary tumor.
BD7 50 Male Negative Carotid body paraganglioma, left
BD8 18 Female NA Jugulotympanic paraganglioma
BD9 28 Male NA Retroperitoneal paraganglioma
BMC Medical Genetics 2009, 10:34 http://www.biomedcentral.com/1471-2350/10/34
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family history in seven out of nine cases strongly indicates
reduced penetrance. Family studies will be extended to
further delineate penetrance and expression.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JPB collected and analyzed the data, co-designed the
study, and wrote the manuscript. MMW and ML edited
and analyzed the data, co-designed the study, and co-
wrote the manuscript. AHV, EPC, and PD designed and
implemented the study, and contributed to the manu-
script. AEMG, PB, MW, HPK, JJ, JWL, RPFD and GPWG
collected and analyzed the data. All authors read and
approved the final manuscript.
Acknowledgements
We would like to thank the patients and their families for their coopera-
tion. This work was partly carried out by Michiel Helmond (student). This 
research was supported by the Dutch Cancer Society (Grant UL 2002–
2723) and the European Union 6th Framework Program (Project No: 
518200). Dr. Robin PF Dullaart represents the Groningen Paraganglioma 
Working Group (GPWG), Department of Endocrinology, Dr TP Links, Dr 
ANA van der Horst).
References
1. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O,
Franke G, et al.: Germ-line mutations in nonsyndromic pheo-
chromocytoma.  N Engl J Med 2002, 346:1459-1466.
2. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D,
Bosch A, et al.: Mutations in SDHD, a mitochondrial complex
II gene, in hereditary paraganglioma.  Science 2000,
287:848-851.
3. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, et al.: Gene
mutations in the succinate dehydrogenase subunit SDHB
cause susceptibility to familial pheochromocytoma and to
familial paraganglioma.  Am J Hum Genet 2001, 69:49-54.
4. Niemann S, Muller U: Mutations in SDHC cause autosomal
dominant paraganglioma, type 3.  Nat Genet 2000, 26:268-270.
5. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J,
Byth K, et al.: Clinical presentation and penetrance of pheo-
chromocytoma/paraganglioma syndromes.  J Clin Endocrinol
Metab 2006, 91:827-836.
6. Mannelli M, Ercolino T, Giache V, Simi L, Cirami C, Parenti G:
Genetic screening for pheochromocytoma: should SDHC
gene analysis be included?  J Med Genet 2007, 44:586-587.
7. Peczkowska M, Cascon A, Prejbisz A, Kubaszek A, Cwikla BJ, Fur-
manek M, et al.: Extra-adrenal and adrenal pheochromocyto-
mas associated with a germline SDHC mutation.  Nat Clin
Pract Endocrinol Metab 2008, 4:111-115.
8. Bayley JP, Devilee P, Taschner PE: The SDH mutation database:
an online resource for succinate dehydrogenase sequence
variants involved in pheochromocytoma, paraganglioma and
mitochondrial complex II deficiency.  BMC Med Genet 2005,
6:39.
9. Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Brocker-
Vriends AH, et al.: Nearly all hereditary paragangliomas in the
Netherlands are caused by two founder mutations in the
SDHD gene.  Genes Chromosomes Cancer 2001, 31:274-281.
10. Bayley JP, van MI, Weiss MM, Jansen JC, Oomen PH, Menko FH, et al.:
Mutation analysis of SDHB and SDHC: novel germline muta-
tions in sporadic head and neck paraganglioma and familial
paraganglioma and/or pheochromocytoma.  BMC Med Genet
2006, 7:1.
11. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F,
Pals G: Relative quantification of 40 nucleic acid sequences by
multiplex ligation-dependent probe amplification.  Nucleic
Acids Res 2002, 30:e57.
12. McWhinney SR, Pilarski RT, Forrester SR, Schneider MC, Sarquis MM,
Dias EP, et al.: Large germline deletions of mitochondrial com-
plex II subunits SDHB and SDHD in hereditary paragangli-
oma.  J Clin Endocrinol Metab 2004, 89:5694-5699.
13. Baysal BE, Willett-Brozick JE, Filho PA, Lawrence EC, Myers EN, Fer-
rell RE: An Alu-mediated partial SDHC deletion causes famil-
ial and sporadic paraganglioma.  J Med Genet 2004, 41:703-709.
14. Cascon A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Leton R,
Rodriguez-Antona C, et al.: Gross SDHB deletions in patients
with paraganglioma detected by multiplex PCR: a possible
hot spot?  Genes Chromosomes Cancer 2006, 45:213-219.
15. Cascon A, Landa I, Lopez-Jimenez E, ez-Hernandez A, Buchta M,
Montero-Conde C, et al.: Molecular characterisation of a com-
mon SDHB deletion in paraganglioma patients.  J Med Genet
2008, 45:233-238.
16. Amar L, Baudin E, Burnichon N, Peyrard S, Silvera S, Bertherat J, et al.:
Succinate dehydrogenase B gene mutations predict survival
in patients with malignant pheochromocytomas or paragan-
gliomas.  J Clin Endocrinol Metab 2007, 92:3822-3828.
17. Fish JH, Klein-Weigel P, Biebl M, Janecke A, Tauscher T, Fraedrich G:
Systematic screening and treatment evaluation of heredi-
tary neck paragangliomas.  Head Neck 2007, 29:864-873.
18. Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S,
Muchow M, et al.: Clinical and molecular genetics of patients
with the Carney-Stratakis syndrome and germline muta-
tions of the genes coding for the succinate dehydrogenase
subunits SDHB, SDHC, and SDHD.  Eur J Hum Genet 2008,
16:79-88.
19. Pigny P, Cardot-Bauters C, Do CC, Vantyghem MC, Carnaille B, Pat-
tou F, et al.: Should genetic testing be performed in each
patient with sporadic pheochromocytoma at presentation?
Eur J Endocrinol 2009, 160:227-231.
20. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR,
Muresan M, et al.: Distinct clinical features of paraganglioma
syndromes associated with SDHB and SDHD gene muta-
tions.  JAMA 2004, 292:943-951.
21. McDonnell CM, Benn DE, Marsh DJ, Robinson BG, Zacharin MR:
K40E: a novel succinate dehydrogenase (SDH)B mutation
causing familial phaeochromocytoma and paraganglioma.
Clin Endocrinol (Oxf) 2004, 61:510-514.
22. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA,
McLeod DR, et al.: Prevalence of SDHB, SDHC, and SDHD
germline mutations in clinic patients with head and neck
paragangliomas.  J Med Genet 2002, 39:178-183.
23. Young AL, Baysal BE, Deb A, Young WF Jr: Familial malignant cat-
echolamine-secreting paraganglioma with prolonged sur-
vival associated with mutation in the succinate
dehydrogenase B gene.  J Clin Endocrinol Metab 2002,
87:4101-4105.
24. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, Solis D,
et al.: Clinical presentations, biochemical phenotypes, and
genotype-phenotype correlations in patients with succinate
dehydrogenase subunit B-associated pheochromocytomas
and paragangliomas.  J Clin Endocrinol Metab 2007, 92:779-786.
25. Mey AG Van Der, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH,
Kamp JJ van de: Genomic imprinting in hereditary glomus
tumours: evidence for new genetic theory.  Lancet 1989,
2:1291-1294.
26. Hensen EF, Jordanova ES, van Minderhout IJHM, Hogendoorn PCW,
Taschner PEM, Mey AGL van der, et al.: Somatic loss of maternal
chromosome 11 causes parent-of-origin-dependent inherit-
ance in SDHD-linked paraganglioma and phaeochromocy-
toma families.  Oncogene 2004, 23:4076-4083.
27. Pigny P, Vincent A, Cardot BC, Bertrand M, de MV, Crepin M, et al.:
Paraganglioma after maternal transmission of a succinate
dehydrogenase gene mutation.  J Clin Endocrinol Metab 2008,
93:1609-1615.
28. Riemann K, Sotlar K, Kupka S, Braun S, Zenner HP, Preyer S, et al.:
Chromosome 11 monosomy in conjunction with a mutated
SDHD initiation codon in nonfamilial paraganglioma cases.
Cancer Genet Cytogenet 2004, 150:128-135.
29. Mircescu H, Wilkin F, Paquette J, Oligny LL, Decaluwe H, Gaboury L,
et al.: Molecular characterization of a pediatric pheochromo-
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Medical Genetics 2009, 10:34 http://www.biomedcentral.com/1471-2350/10/34
Page 10 of 10
(page number not for citation purposes)
cytoma with suspected bilateral disease.  J Pediatr 2001,
138:269-273.
30. Margetts CDE, Astuti D, Gentle DC, Cooper WN, Cascon A, Catch-
poole D, et al.: Epigenetic analysis of HIC1, CASP8, FLIP,
TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferen-
tial 11p15.5 maternal-allele loss in von Hippel-Lindau and
sporadic phaeochromocytomas.  Endocrine-Related Cancer 2005,
12:161-172.
31. Gottlieb E, Tomlinson IP: Mitochondrial tumour suppressors: a
genetic and biochemical update.  Nat Rev Cancer 2005,
5:857-866.
32. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, et al.: Neu-
ronal apoptosis linked to EglN3 prolyl hydroxylase and famil-
ial pheochromocytoma genes: developmental culling and
cancer.  Cancer Cell 2005, 8:155-167.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2350/10/34/pre
pub
